Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

Also called NCT03086330

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 302 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03086330
  • EudraCT 2016-000904-27
Main results
  • Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial The lancet. Diabetes & endocrinology, 2019-05 DOI, PubMed 30833170 PubMed links an erratum for this paper. Erratum: PMID 30872122; Erratum: PMID 31272930; Erratum: PMID 31621596

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Canada, Japan, Norway, Puerto Rico, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03086330. Randomized; double masking; primary purpose treatment. Start 2017-03-15 (actual); primary completion 2018-07-04 (actual). Results posted on 2019-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Acronym
SUSTAIN 9
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03086330
Content hash
af508b1c6fb7ed023a606aba58ed0b8704353152a8a4acc6dc4372ae72903f0a